IVHEM_2025_Emblem
Meeting category
Date(s)
10 Jan 2025 - 11 Jan 2025
Important dates
Extended Abstract Submission Deadline
Friday, 1 November 2024 at 23:59 KST
Program Language
English
Location
Seoul, South Korea
Meeting type
Live Meeting
Meeting Organizers
Co-Convener
Sponsor logos
Coalition for Global Hepatitis Elimination

11th International Viral Hepatitis Elimination Meeting (IVHEM) 2025

General
What's New
  • The Abstract Submission Deadline for the 11th IVHEM is extended to Friday, 1 November 2024 at 23:59 KST. For more information, please check the "Abstracts" tab.

  • 11th edition of the International Viral Hepatitis Elimination Meeting (IVHEM) will be held on 10-11 January 2025 in Seoul, South Korea.

  • Registration for the 11th IVHEM is open! Check out each respective tab for more information.

  • To stay updated on the relevant developments, make sure you are signed up for our newsletter. 

Welcome

Convened by Academic Medical Education and the Coalition for Global Hepatitis Elimination (CGHE), the International Viral Hepatitis Elimination Meeting (IVHEM) is a global forum for the exchange of practical experiences for translating diagnostic and therapy advances of viral hepatitis into broad applications that accelerate progress towards the elimination of viral hepatitis as a public health threat by 2030.

Hepatitis B and C affect more than 354 million people globally and can lead to liver disease and mortality from liver failure and hepatocellular carcinoma. More than 296 million people (3.7% of the world’s population) live with HBV, and over 820,000 deaths are attributable annually. An estimated 58 million people (globally, 0.73%) live with the hepatitis C virus (HCV), resulting in nearly 290,000 deaths annually.

Key issues to be addressed are how to translate research outcomes into public health policy and practice to meet the 2030 elimination targets. During this two-day meeting, experts in viral hepatitis from around the globe will examine current evidence on how to implement programs that improve the prevention of viral hepatitis and increase the number of people accessing testing and treatment.

The program includes practical examples of innovative intervention studies, country elimination programs, and novel funding mechanisms for testing and treatment.

We invite you to contribute to the elimination of viral hepatitis and look forward to welcoming you to this unique meeting either in person or virtually!

The Organizing Committee

Program Chairs
Ward, John 2023
John Ward, MD
Coalition for Global Hepatitis Elimination, Task Force for Global Health / Rollins School of Public Health, Emory University, United States
Organizers

IVHEM is convened by Academic Medical Education and the Coalition for Global Hepatitis Elimination (CGHE).

Local Partners
Venue
Information regarding the meeting venue for the 11th International Viral Hepatitis Elimination Meeting (IVHEM) will be provided soon.
COVID-19 Update
Responding to the changing COVID-19 situation, the International Viral Hepatitis Elimination Meeting (IVHEM) 2024 will be held as a hybrid meeting. This workshop format is an optimal solution in light of the current circumstances.

We are available to answer any questions or concerns that you may have about your participation. For more information, please contact Michelle Wu via Michelle.Wu@amededu.com.
Who Should Attend?
- Healthcare professionals
- Clinicians
- Researchers
- Policymakers
- Virologists
- Pharmacologists
- Industry representatives
- Community representatives
Meeting Objectives
This meeting aims to:

- Provide a forum for knowledge exchange and discussion of practical experiences related to the clinical management of viral hepatitis;
- Provide a toolbox for the practical application of research & development for evidence-based policymaking; and
- Facilitate cross-disciplinary discussion on barriers and challenges preventing the elimination of viral hepatitis.
Learning Objectives
After participating in this activity, participants will be able to:

- Identify innovative strategies for hepatitis b and hepatitis C testing and linkage to care and how these can be applied to their program and clinical activities;
- Recognize the needs from a public health perspective and respond to these needs by reshaping their policymaking approaches;
- Further develop new or strengthen already existing foundations for political commitment, national planning, and program improvements; and
- Translate the latest research and technologies into clinical policy and practice for delivering an adequate continuum of viral hepatitis services.

Practical Information

Certificate of Attendance
A certificate of attendance will be sent to participants who successfully complete the meeting and post-meeting survey.
Language
The official language of the workshop is English.
Translation will not be provided.
Enduring Materials
Enduring materials will be available after the conclusion of the meeting.
Disclaimer
This meeting is intended for educational purposes only and aims to offer participants the opportunity to share information. The Organizing Secretariat of this meeting, AME, cannot accept any liability for the scientific content of the sessions or for any claims which may result from the use of information or publications from this meeting. AME disclaims all liability for injuries or losses of whatever nature incurred by individuals attending the meeting.
Liability and Insurance
By registering for the meeting, participants agree that the organizers do not accept responsibility for medical-, travel- or personal insurance. Participants are advised to take out their own insurance policies.
Photographs, Audio, and Video Recording
Photographs, audio, and video recordings are not permitted at the official meeting sessions. Only the official medical writer appointed by the organization may make recordings. All presentations will be posted here as soon as possible after the meeting is finished, provided that the speaker has given permission to do so.
Code of Conduct
All attendees, speakers, co-organizers, partners, endorsers, suppliers, volunteers, and employees at any of our programs are expected to observe our Code of Conduct. We cannot tolerate any form of discrimination, harassment, disrespect, or the marginalization of those involved in our programs. All participants of AME-organized programs are expected to treat others with dignity and respect at all times.

Any individual who feels discriminated against, harassed, disrespected, or marginalized is encouraged to report the incident(s) to AME via info@amededu.com or to one of our on-site personnel.

Any participant who is found to have exhibited any inappropriate conduct or behavior against others may be removed from the program.
Program
Preliminary Program

The below times are set in Korean Standard Time (KST). Please, use this tool to convert the timing into your time zone.

DAY 1 - Friday, 10 January 2025

- 07:30
07:30
Registration Desk Open
          
Session 1: Status of Hepatitis Elimination in Globally and Asia - 09:00
09:00
Opening & Welcome
Hepatitis Elimination in Asia
An Introduction to Hepatitis Elimination in Republic of Korea
10:15
Coffee Break
      
Oral Abstract Presentations I - 12:00
12:00
Oral Abstract Presentation #1
Oral Abstract Presentation #2
Oral Abstract Presentation #3
Oral Abstract Presentation #4
Discussion
13:00
Lunch
     
Session 3: Health Equity - Viral Elimination in Priority Populations - 14:00
14:00
Lecture - TBD
Korea HCV Screening in Correctional Facilities
Discussion
Oral Abstract Presentations II - 15:15
15:15
Oral Abstract Presentation #5
Oral Abstract Presentation #6
Oral Abstract Presentation #7
Oral Abstract Presentation #8
Discussion
16:15
Coffee Break
     
Session 4: Expanding Access to HBV Treatment - 16:45
16:45
Opportunities and Challenges for Implementing WHO Recommendations in Asia
Status of Recent Chinese Guidelines
Evaluation of Thai Guidelines for Integrated HBV and HCV Screening and Care
Launch of a Coordination Center for HBV Care Research in LMICs COR-HEPB
18:00
Poster Viewing & Welcome Reception
       

DAY 2 - Saturday, 11 January 2025

Session 5: Out of The Shadow - Hepatitis Delta Virus - 09:00
09:00
Hepatitis D: A Reappraisal
Pacific Countries
Discussion
10:00
Coffee Break
        
Oral Abstract Presentations III - 11:45
11:45
Oral Abstract Presentation #9
Oral Abstract Presentation #10
Oral Abstract Presentation #11
Oral Abstract Presentation #12
Discussion
12:45
Lunch
Session 7: Innovation in Prevention, Diagnosis and Treatment - 13:45
13:45
Industry Representative Talk 1
Industry Representative Talk 2
Industry Representative Talk 3
Industry Representative Talk 4
Panel Discussion
Oral Abstract Presentations IV - 15:00
15:00
Oral Abstract Presentation #13
Oral Abstract Presentation #14
Oral Abstract Presentation #15
Oral Abstract Presentation #16
Discussion
16:00
Coffee Break
Session 8: Comorbids and Coinfections - 16:30
16:30
HCC Surveillance Using Blood-Biomarkers (GALAD and GAAD Scores)
Oral Abstract Presentation #17
Oral Abstract Presentation #18
17:15
Closing Remarks
Registration
Early Registration Fee deadline is extended!
Fees and Conditions

Regular Delegates

 In Person 

Regular Delegates

 Virtual

Industry

In Person

Industry

 Virtual

Early Fee (payment before/on 3 November 2024)

€395

€295

€695

€595

Standard Fee (payment before/on 29 December 2024)

€595

€495

€895

€795

Late Fee (payment from 30 December 2024)

€695

€595

€995

€895

Discounts

Early-Career Investigators WITH an accepted abstract

50% discount on Early Registration Fee

Regular Delegates from Resource-Limited Settings (RLS)* WITH an accepted abstract

Complimentary Registration

Early-Career Investigators / Regular Delegates from Resource-Limited Settings (RLS)* WITHOUT an accepted abstract

50% discount on Current Regular Delegates Fee

NGO Representatives / Government Representatives (i.e. MOH, NIH, NIAID, etc.) / Advocates

50% Off Current Regular Delegates Fee

Members of Endorsers

25% Off Current Regular Delegates Fee

 Sponsors

Contact Secretariat

If eligible for a discount, please contact the conference secretariat via Michelle Wu via Michelle.Wu@amededu.com for the special registration code.

*Countries included in the low-income and middle-income economies list of the World Bank Classification

Important
  • We strongly advise that you register early to ensure that your registration is secured.

  • Submission of your online registration does not guarantee that your registration has been accepted. Your registration is final when full prepayment has been received and a confirmation of your registration has been sent.

  • No day rate is available.

Registration Fee Includes
For onsite attendees, including Regular Delegates In-Person Attendees and Industry Representatives In-Person Attendees:

- Access to all scientific sessions, including poster area

- Conference pack, including virtual abstract book and printed program book

- Refreshments during the coffee breaks

- Buffet lunch on meeting days

- Complimentary entrance to the Networking Reception*

* The Networking Reception will take place in the same venue of the meeting and will not have any music / entertainment of any shape or form. The Networking Reception only offers finger foods and the opportunity to have a look at the chosen abstract poster presentations.


For virtual attendees, including Regular Delegates Virtual Attendees and Industry Representatives Virtual Attendees only:

- Access to all scientific sessions

- Digital workshop pack, including the digital program book and digital abstract book.


IMPORTANT:

- No day rate is available

- The Networking Dinner is not included in the registration fee. Should you wish to attend the Networking Dinner, an additional fee of €60 is charged. Pre-booking is required via the conference secretariat.

- Academic Medical Education reserves the right to cancel improper registrations. Claims for a refund will not be honored.
Group Registration
For group registration, please contact Michelle Wu at Michelle.Wu@amededu.com.
Academia from Resource-limited Settings (RLS) / Early-Career Investigators
We are pleased to waive the registration fee for early-career investigators and academia from low-income and lower-middle-income countries with an accepted abstract and also provide a 50% discount on the registration fee for those without an accepted abstract.

IMPORTANT: the registration fee waiver is offered to the presenting author only.

To be eligible as a young investigator, one should either be:
a current Master/PhD student, or
have obtained an MD/PharmD/PhD degree in the last five years.

An application form (available below) needs to be completed by a supervisor and received by the secretariat at least two weeks prior to the start of the workshop. AME and VE will contact the investigator with instructions regarding the registration procedure.
Sponsored Attendance
If you are invited by a pharmaceutical or diagnostic company, or if your registration is organized by a travel agency, please do not register online. The sponsoring company will be asked to register you via the conference secretariat.
Payment
By credit card only: online or by written authorization.

Please contact Michelle Wu at Michelle.Wu@amededu.com if you need to make alternative arrangements.
Cancellation Policy
In case of cancellation, the following refunds are applicable:

- Cancellation before/on 8 December: 50% refund (minus an administration fee of €40)
- Cancellation after 8 December : Unfortunately, no refund will be given

If you are unable to attend the meeting, a substitute delegate is always welcome at no extra charge, provided that a letter of authorization from the original participant has been received and the conference secretariat has been notified of the name of the substitute delegate 2 weeks before the meeting. A statement (email/letter) of cancellation must be sent to AME.
Liability and Insurance
By registering for the meeting, participants agree that the organizers do not accept responsibility for medical, travel, or personal insurance. Participants are advised to take out their own insurance policies.
Media Registration
In order to register as a media participant for the meeting, the conference secretariat needs to receive:

1. Proof of accreditation
2. Valid identification (e.g. passport)
3. A letter from your assignment giver stating the details of your assignment (e.g. editor)
4. At least 3 previous written assignments in recognized outlets on Hepatitis. If you are a freelance journalist, the assignments can be from different (recognizable) news outlets. Links to online publications are accepted
5. The website of the publication(s)/blog(s) that will be featuring your story on this meeting

A free or reduced registration fee may apply for accredited media participants depending on availability. Preference will be given to credible print and online news sources. Please contact the conference secretariat for registration conditions.

We would like to receive a copy of your meeting report/ article once it is finalized.
All credentials will be verified by the Organizing Committee of the meeting. Media representatives are kindly requested to register by sending the above-mentioned information to info@amededu.com.

Important: Media is restricted to the written press. Recording on film or photo is not allowed. AME will request a copy of the written piece once it is finalized. Media representatives must also agree to abide by the 2024 embargo policy.
Disclaimer
This meeting is intended for educational purposes only and aims to offer participants the opportunity to share information. The organizing secretariat of this meeting, AME, cannot accept any liability for the scientific content of the sessions or for any claims which may result from the use of information or publications from this meeting. AME disclaim all liability for injuries or losses of whatever nature incurred by individuals attending the meeting. In case of cancellation of the meeting due to unforeseen circumstances, AME cannot be held responsible for expenses made for travel, accommodation, visa applications, etc.
Abstracts

The abstract submission portal is still open!

Abstracts
  • Abstract submission portal for the 11th IVHEM will be open until Friday, 1 November 2024 at 23:59 KST.

  • Registration fees are waived for healthcare professionals from RLS and early-career professionals with an accepted abstract. A 50% discount is offered to healthcare professionals from RLS and early-career professionals without an accepted abstract. The requirements for the application are specified under "Registration".

  • 11th IVHEM accepts new original data as well as encored abstracts. All abstracts must focus on health care challenges related to the prevention and treatment of Hepatitis and contain up-to-date information at the time of the meeting. 

Terms and Conditions

By submitting an abstract to a meeting organized by Academic Medical Education BV (AME), the abstract submitter hereby agrees to the terms and conditions.

The terms and conditions can be viewed here

Categories for Abstract Submission
For purposes of review and programming, abstracts are divided into topical categories. The selection of the most appropriate category is important as it determines who reviews your abstract. The Organizing Committee reserves the right to reassign your abstract to a more appropriate category.

IVHEM accepts abstracts related to all viral hepatitis variants (HAV, HBV, HCV, HDV, and HEV) and coinfections. Abstracts can be submitted under the following categories:

- Assessing Progress Towards Hepatitis Elimination
- Hepatitis Micro-Elimination Programs
- Key Populations
- Model for Care
- Monitoring and Testing
- Prevention
- Strategies to Move Forward to Come to Elimination
General Guidelines
Abstracts should contain the following four components:

- Background: A concise statement of the issue under investigation or a hypothesis;
- Material and Methods: The experimental methods used (including the statistical analyses employed);
- Results: Specific findings (promises such as "to be completed" or "to be presented" are not acceptable);
- Conclusions: A summary of findings that are supported by your results (statistical analyses used to support the conclusions, where appropriate, should be included; concluding statements such as "the results will be discussed" are not acceptable).

Please note that abstracts cannot be accepted if tables or graphs are included. The maximum word count for the abstract body is 500 words.

Abstracts are considered official communications to the meeting and will be treated confidentially. Submitters of accepted abstracts agree to attend the meeting and present their abstract as scheduled.
Abstract Submission
Authors can submit their abstracts electronically. You will be redirected to the submission website. Please follow the step-by-step directions to upload the abstract. To ensure your abstract retains any special characters or formatting, the abstract must be in Microsoft Word format.
Poster Presentation Instructions for Virtual Meeting
- Digital Posters must be prepared in PDF.
- The measurements of your poster should not exceed two Letter/ A4 format pages, make sure the quality of your poster is good (at least 300 dpi).
- Please display the number of your poster in the upper right corner of your poster.
- If you wish to allow people to reach out directly to you, please display your contact details on your poster. Participants will be also able to contact you directly via Meeting Hub in the OnAir Portal.
- Instructions on how to upload your digital poster to the Virtual Meeting Portal / Virtual Poster Gallery will be sent shortly before the meeting day.
- Your poster will be displayed in the virtual Poster Gallery throughout the meeting.
Poster Presentation Instructions for In Person Meeting
- Posters need to meet the following dimensions: A0 size (approx 33" width x 47" height), portrait format
- Poster presenters are requested to stand near their posters during the poster session.
- Please hang your posters as early as possible. All posters must be displayed from the opening session to the closure of the meeting.
- Pushpins and/or tape will be provided.
Abstract Publication
Accepted abstracts will be published in the Abstract Book of the 11th IVHEM. This will be available as enduring material after the meeting has concluded. Please note that the conference secretariat cannot be held responsible for any typing or language errors in the submitted abstracts as only the format of the abstracts will be changed and not the content.

AME is the sole copyright holder of the conference abstract book as a whole. The abstract authors will retain any and all copyright over their individual abstract. Information on copyright can be viewed in the abstract submission terms and conditions (see 'Terms and Conditions' above).
Committees
Program Chairs
Ward, John 2023
John Ward, MD
Coalition for Global Hepatitis Elimination, Task Force for Global Health / Rollins School of Public Health, Emory University, United States
Organizing Committee
No Photo_Faculty
George Lau, MD, FRCP, FAASLD
APASL Viral Elimination Task Force, Hong Kong

The members of the Organizing Committee are a group of carefully selected experts and inspirational leaders in their respective fields. They meet frequently to discuss the scientific program of the workshop, identify interesting topics and candidate speakers, and review all submitted abstracts.

Scientific Committee
  • Rakesh Aggarwal, MD (AIIMS), DM (PGIMER), FNASc, FAMS - Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), India

  • Po-Lin Chan, MD - World Health Organization, Philippines

  • Graham Cooke, MD, PhD - Imperial College London, United Kingdom

  • Gagandeep Singh Grover, MD - Health and Family Welfare, India

  • Saeed Hamid, MBBS, FRCP, FRCPI, FACP, FACG, FAASLD - Aga Khan University, Pakistan

  • Angelos Hatzakis, MD, PhD, MSc - Athens University Medical School, Greece

  • Margaret Hellard, AM, MBBS, FRACP, FAFPHM, PhD - Burnet Institute, Australia

  • Khin Pyone Kyi, MBBS, DBact, MMedSc, PhD, FRCP - Myanmar Liver Foundation, Myanmar

  • Maud Lemoine, MD, PhD - Imperial College London, United Kingdom

  • Liudmyla Maistat - Medicines Patent Pool, Switzerland

  • Hailemichael Desalegn Mekonnen, MD, PhD - St. Paul’s Hospital Millennium Medical College, Ethiopia

  • Yvonne Nartey, MBChB, MSc, MPhil – Cape Coast Teaching Hospital, Ghana

  • Michael Ninburg, Hepatitis Education Project (HEP), United States

  • Ponsiano Ocama, MD, PhD - Makerere University, Uganda

  • Jean-Michel Pawlotsky, MD, PhD - Hôpital Henri Mondor, France

  • Homie Razavi, PhD, MBA - Center for Disease Analysis (CDA), United States

  • Shiv. K. Sarin, MD, DM, DSc. (Hony.), FNA, FNAS - Institute of Liver and Biliary Sciences (ILBS), India

  • Janvier Serumondo, MD - Rwanda Biomedical Centre, Rwanda

  • Marcelo Silva, MD - Latin American Association for the Study of the Liver, Austral University Hospital, Argentina

  • Mark Sonderup, B Pharm, MBChB, FCP(SA), MMed - University of Cape Town, South Africa

  • Sonjelle Shilton, MPH - Foundation for Innovative New Diagnostics (FIND), Switzerland

  • Nasamon Wanlapakorn, MD, PhD - Chulalongkorn University, Thailand

The members of Scientific Committee are hand-picked by the Organizing Committee and the workshop secretariat based on their significant contributions and commitment to the field. They assist the Organizing Committee by providing them with suggestions for speakers and topics. In addition, members of the Scientific Committee participate in reviewing submitted abstracts, and play an active role during the workshop as moderators and/or chairs of sessions.

Local Partners
Korea Disease Control and Prevention Agency (KDCA)
The Korea Disease Control and Prevention Agency (KDCA) is the national public health response organisation in South Korea, established in January 2004 as the Korea Centres for Disease Control and Prevention (KCDC) and elevated to KDCA for the 2020 COVID-19 pandemic response. The KDCA has designated hepatitis A, B, C and E as statutory infectious diseases for the prevention and management of viral hepatitis. In March 2023, in line with the World Health Organization's goal to eliminate hepatitis B and C by 2030, the KDCA established the 1st National Strategic Plan for Viral Hepatitis(B and C) Control(2023-2027) to lay the foundation for the elimination of viral hepatitis. In particular, one of the key tasks of the plan was to expand screening test for hepatitis C. In July 2024, it was decided to introduce a hepatitis C antibody test in the national health Screening Program. Accordingly, from 2025, hepatitis C antibody tests will be conducted for people aged 56 years and older, and a follow-up plan will be prepared. The Korea Disease Control and Prevention Agency (KDCA) is actively cooperating with the international community and international organisations to eliminate viral hepatitis, and the 11th IVHEM in Seoul will be held in cooperation with the CGHE.
Korean Association for the Study of the Liver (KASL)
The Korean Association for the Study of the Liver (KASL), originally founded as the “Korean Society for the Study of Liver” in 1981 and officially established in 1995, has evolved into a leading organization, serving as a model for national liver associations worldwide. KASL has earned international recognition for its contributions to liver disease research and treatment. Its annual event, "The Liver Week," has become a prominent global academic conference. In 2024, The Liver Week attracted 1,306 participants from 27 countries and received 713 abstracts. KASL's official journal, Clinical and Molecular Hepatology, is projected to achieve an Impact Factor of over 14.0, ranking 6th out of 143 journals in Gastroenterology and Hepatology. KASL is committed to fostering academic exchange and policy development within the liver research community. In collaboration with the Korean Liver Foundation, KASL conducts workshops on clinical research methodology and organizes nationwide public awareness events, such as Liver Day. KASL also actively participates in shaping national healthcare policies, providing vital support for clinical research and treatment initiatives by its members.
Support
Support Our Initiative

Financial backing to the 11th International Viral Hepatitis Elimination Meeting (IVHEM) helps us deliver an impactful meeting experience for the benefit of healthcare professionals and community representatives involved in the elimination of viral hepatitis.
 
This collaboration plays a vital role in both the organizational as well as scientific success of the program.
 
To show your commitment to the cause and get in touch with us for a tailored support package, please contact us at Michelle.Wu@amededu.com.

Benefits of Support 
By supporting this program, we can offer the following advantages for your company.* Please contact us for the most recent support level benefits for this program.

  • Symposium opportunities
  • Verbal acknowldgment during the program 
  • Discounted and complimentary registrations for your representatives
  • Company acknowldgment on digital meeting materials including but not limited to newsletters, flyers, program book, the streaming platform, and our website
  • Digital advertising opportunities 
  • Social media shout-outs
  • Logo on the digital conference bag 
  • Exhibition

 
*Subject to the support level

Endorsers
Previous Editions
Language